SPOTLIGHT -
CMS grants Transitional Pass-Through payment status to flotufolastat F 18
The reimbursement code for flotufolastat F 18 will be effective October 1, 2023.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Postoperative Urinary Retention – AUGS Publications Committee Interview
Dr. Kate Meriwether, AUGS Publications Committee member, interviews Dr Colleen McDermott, the first author of the Clinical Consensus Statement “Postoperative Urinary Retention,” to provide an overview and highlight the findings of the document.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Hybrid approach to telehealth effective in rural communities
“A hybrid telehealth approach expands access to specialized care, reduces travel burdens, promotes timely interventions, and enables continuous management of health conditions,” writes Kara Hartl, MD.
Adding SBRT to frontline abiraterone shows benefit in oligometastatic CRPC
The addition of SBRT to upfront abiraterone acetate and prednisone (AAP) reduced the risk of disease progression or death by 65% compared with AAP alone in patients with oligometastatic castration-resistant prostate cancer.
